Heterozygous Familial Hypercholesterolemia (HeFH) research hub
4 indexed studies · 4 currently recruiting
- recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia
This study is testing a new tablet, MK-0616, for adults with a condition called Heterozygous Familial Hypercholesterolemia (HeFH). We want to see if it lowers 'bad' cholesterol (LDL-C) and if it's safe to use. Half the people will get the new tablet, and half will get a dummy tablet.
Finland · Norway · Spain - recruitingPHASE1
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
This study is testing a new medicine called CTX310 for people in the UK with high cholesterol and fats in their blood that haven't improved with usual treatments. It will check if the medicine is safe and how well people tolerate different doses. It's an early-stage study.
United States · Australia · New Zealand - not yet recruitingNA
"Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)"
This study looks at how heart artery narrowing develops over 5 years in people with a genetic condition called Familial Hypercholesterolemia. It uses special MRI scans to see changes in arteries and understand the condition better.
France - recruitingPHASE2, PHASE3
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
This study is looking at a new oral medicine, enlicitide decanoate, for children and teenagers aged 6-17 with a condition called Heterozygous Familial Hypercholesterolemia (HeFH). We want to see if it's safe and helps lower high cholesterol levels.
United States · Australia · Belgium